Matinas Biopharma Holdings, Inc.

Common Stock SEC Reporting - Current
Verified Company Profile 9/20/2016
Contact Info
  • 1545 Route 206 South
  • Suite 302
  • Bedminster, NJ 07921

Business Description

Financial Reporting/Disclosure
Reporting Status U.S. Reporting: SEC Reporting
Audited Financials Audited
Latest Report Jun 30, 2016 10-Q
CIK 0001582554
Fiscal Year End 12/31
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Business Status Development Stage Company a/o Mar 19, 2015
Incorporated In: DE, USA
Year of Inc. 2013
Employees 10 a/o Mar 23, 2016
Company Officers/Contacts
Roelof Rongen CEO
Jerry Jabbour President, General Counsel, EVP
Gary Gaglione Interim CFO
Abdel Fawzy EVP, Bus. Affairs
Douglas F. Kling Senior VP
Raphael J. Mannino CSO, CTO
Company Directors
Herbert Conrad Chairman
Stefano Ferrari
Roelof Rongen
James Scibetta
Adam Stern
Service Providers
Accounting/Auditing Firm
EisnerAmper LLP
111 Wood Avenue South
Suite 600
Iselin, NJ, 08830-2700
United States

Legal Counsel
Lowenstein Sandler LLP (NJ)
65 Livingston Avenue
Roseland, NJ, 07068
United States

Investor Relations Firm
Jenene Thomas Communications, LLC
48 Sky Manor Road, G4
Pittstown, NJ, 08867
United States

MTNB Security Details
Share Structure
Market Value1 $81,078,780 a/o Oct 27, 2016
Authorized Shares 250,000,000 a/o Sep 23, 2016
Outstanding Shares 57,913,414 a/o Sep 23, 2016
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 26,076,909 a/o Sep 08, 2016
Par Value Not Available
Transfer Agent(s) Verified by Transfer Agent
VStock Transfer LLC
Shareholders of Record 328 a/o Sep 08, 2016
Short Selling Data
Short Interest 41,997 (890.73%)
Sep 15, 2016
Significant Failures to Deliver No

1Market Value calculated only for respective security